DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
EMA Press release 25/07/2014. European Medicines Agency recommends approval of two new treatment options for rare cancers: Imbruvica and Zydelig to be used in different forms of blood cancers.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.